Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.

Autor: Yiğit Kaya S; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Turkey. Electronic address: sureyya.yigitkaya@medipol.com.tr., Mutlu YG; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey., Malkan ÜY; Department of Hematology, Faculty of Medicine, Hacettepe University, Turkey., Mehtap Ö; Department of Hematology, Faculty of Medicine, Kocaeli University, Turkey., Keklik Karadağ F; Department of Hematology, Faculty of Medicine, Ege University, Turkey., Korkmaz G; Department of Hematology, Ankara Bilkent City Hospital, Turkey., Elverdi T; Department of Hematology, Cerrahpaşa Faculty of Medicine, Istanbul University, Turkey., Saydam G; Department of Hematology, Faculty of Medicine, Ege University, Turkey., Özet G; Department of Hematology, Ankara Bilkent City Hospital, Turkey., Ar MC; Department of Hematology, Cerrahpaşa Faculty of Medicine, Istanbul University, Turkey., Melek E; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey., Maral S; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey., Kaynar L; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey., Sevindik ÖG; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2024 May; Vol. 140, pp. 107495. Date of Electronic Publication: 2024 Mar 29.
DOI: 10.1016/j.leukres.2024.107495
Abstrakt: Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. The BRAF V600E mutation prevalent in HCL patients provides a target for treatment with vemurafenib.
Patients and Methods: This multicenter retrospective study included nine patients with relapsed/refractory (R/R) HCL from six different centers. Patient data included demographics, prior treatments, clinical outcomes, and adverse events.
Results: Patients received different treatment regimens between centers, including vemurafenib alone or in combination with rituximab. Despite the differences in protocols, all patients achieved at least a partial response, with seven patients achieving a complete response. Adverse events were generally mild with manageable side effects. The absence of myelotoxic effects and manageable side effects make BRAF inhibitors attractive, especially for patients ineligible for purine analogues or those with severe neutropenia.
Conclusion: Single agent vemurafenib or in combination with rituximab appears to be a promising therapeutic option for R/R HCL. Further research is needed to establish standardized treatment protocols and to investigate long-term outcomes.
Competing Interests: Declaration of Competing Interest All of the authors declare that there is no conflict of interest.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: